AllianceBernstein’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-33,580
| Closed | -$542K | – | 3381 |
|
|
2026
Q1 | $542K | Sell |
33,580
-6,440
| -16% | -$104K | ﹤0.01% | 2598 |
|
|
2025
Q4 | $646K | Hold |
40,020
| – | – | ﹤0.01% | 2532 |
|
|
2025
Q3 | $487K | Hold |
40,020
| – | – | ﹤0.01% | 2694 |
|
|
2025
Q2 | $452K | Hold |
40,020
| – | – | ﹤0.01% | 2702 |
|
|
2025
Q1 | $462K | Hold |
40,020
| – | – | ﹤0.01% | 2588 |
|
|
2024
Q4 | $339K | Hold |
40,020
| – | – | ﹤0.01% | 2810 |
|
|
2024
Q3 | $463K | Sell |
40,020
-2,430
| -6% | -$30.6K | ﹤0.01% | 2692 |
|
|
2024
Q2 | $500K | Buy |
42,450
+12,440
| +41% | +$145K | ﹤0.01% | 2667 |
|
|
2024
Q1 | $356K | Hold |
30,010
| – | – | ﹤0.01% | 2740 |
|
|
2023
Q4 | $368K | Sell |
30,010
-2,400
| -7% | -$21.8K | ﹤0.01% | 2758 |
|
|
2023
Q3 | $312K | Hold |
32,410
| – | – | ﹤0.01% | 2790 |
|
|
2023
Q2 | $292K | Buy |
32,410
+6,710
| +26% | +$61.9K | ﹤0.01% | 2872 |
|
|
2023
Q1 | $202K | Hold |
25,700
| – | – | ﹤0.01% | 2903 |
|
|
2022
Q4 | $174K | Buy |
25,700
+8,636
| +51% | +$46.3K | ﹤0.01% | 3034 |
|
|
2022
Q3 | $248K | Buy |
17,064
+1,964
| +13% | +$27.5K | ﹤0.01% | 2945 |
|
|
2022
Q2 | $149K | Buy |
15,100
+4,700
| +45% | +$51.8K | ﹤0.01% | 3074 |
|
|
2022
Q1 | $153K | Sell |
10,400
-1,800
| -15% | -$25.9K | ﹤0.01% | 3050 |
|
|
2021
Q4 | $161K | Hold |
12,200
| – | – | ﹤0.01% | 3126 |
|
|
2021
Q3 | $213K | Hold |
12,200
| – | – | ﹤0.01% | 3069 |
|
|
2021
Q2 | $292K | Buy |
+12,200
| New | +$319K | ﹤0.01% | 3017 |
|
|
2021
Q1 | – | Sell |
-18,800
| Closed | -$357K | – | 3267 |
|
|
2020
Q4 | $357K | Sell |
18,800
-900
| -5% | -$15.4K | ﹤0.01% | 2768 |
|
|
2020
Q3 | $248K | Hold |
19,700
| – | – | ﹤0.01% | 2891 |
|
|
2020
Q2 | $238K | Buy |
19,700
+7,400
| +60% | +$78.7K | ﹤0.01% | 2958 |
|
|
2020
Q1 | $94K | Buy |
12,300
+2,200
| +22% | +$29.7K | ﹤0.01% | 2971 |
|
|
2019
Q4 | $180K | Hold |
10,100
| – | – | ﹤0.01% | 2944 |
|
|
2019
Q3 | $117K | Buy |
+10,100
| New | +$163K | ﹤0.01% | 3051 |
|
Other funds holding KALV
AllianceBernstein's KALV Position: Q2 2026 in Review
AllianceBernstein sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 33,580 shares — an estimated $542K sold.
AllianceBernstein first reported a position in KALV in Q3 2019 and held it in 26 quarters. The position peaked at $646K in Q4 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- AllianceBernstein reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- AllianceBernstein sold 33,580 KalVista Pharmaceuticals shares in Q2 2026, an estimated $542K.
- AllianceBernstein first reported a position in KalVista Pharmaceuticals in Q3 2019 and held it in 26 quarters.
- AllianceBernstein's KalVista Pharmaceuticals position peaked at $646K in Q4 2025.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.